EPW
HQL

Evolve Private Wealth’s abrdn Life Sciences Investors HQL Stock Holding History

Evolve Private Wealth’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
11,754
-100
-0.8% -$1.67K 0.01% 941
2025
Q4 		$199K Buy
+11,854
New +$199K 0.01% 874

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Evolve Private Wealth's HQL Position: Q1 2026 in Review

Evolve Private Wealth reduced its abrdn Life Sciences Investors (HQL) stake by 0.84% in Q1 2026, selling an estimated $1.67K and leaving 11,754 shares worth $191K. The position accounts for 0.01% of the portfolio, ranked #941.

Evolve Private Wealth first reported a position in HQL in Q4 2025 and has held it in 2 quarters since. The position peaked at $199K in Q4 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Evolve Private Wealth held 11,754 shares of abrdn Life Sciences Investors worth $191K as of Q1 2026.
  • Evolve Private Wealth sold 100 abrdn Life Sciences Investors shares in Q1 2026, an estimated $1.67K.
  • abrdn Life Sciences Investors made up 0.01% of Evolve Private Wealth's portfolio in Q1 2026, its #941 holding.
  • Evolve Private Wealth first reported a position in abrdn Life Sciences Investors in Q4 2025 and has held it in 2 quarters since.
  • Evolve Private Wealth's abrdn Life Sciences Investors position peaked at $199K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Evolve Private Wealth's 13F filing for Q1 2026, filed 16 Apr 2026.